|
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12e
| Section III. Modulation of Cardiovascular Function > |
Chapter 31. Drug Therapy for Hypercholesterolemia and Dyslipidemia
Sections: Drug Therapy for Hypercholesterolemia and Dyslipidemia: Introduction, Plasma Lipoprotein Metabolism, Hyperlipidemia and Atherosclerosis, Drug Therapy of Dyslipidemia, Clinical Summary, BIBLIOGRAPHY.
Topics Discussed: dyslipidemias; hypercholesterolemia; lipid-lowering therapy; lipids as drug targets; pharmacotherapy of cardiovascular disorders.
Excerpt:"Hyperlipidemia is a major cause of atherosclerosis and atherosclerosis-induced conditions, such as coronary heart disease (CHD), ischemic cerebrovascular disease, and peripheral vascular disease. Although the incidence of these atherosclerosis-related cardiovascular disease (CVD) events has declined in the U.S., these conditions cause morbidity or mortality in a majority of middle-aged or older adults and account for about one-third of all deaths of persons in this age range. The incidence and absolute number of annual events will likely increase over the next decade because of the epidemic of obesity and the aging of the U.S. population. Dyslipidemias, including hyperlipidemia (hypercholesterolemia) and low levels of high-density-lipoprotein cholesterol (HDL-C), are major causes of increased atherogenic risk; both genetic disorders and lifestyle (sedentary behavior and diets high in calories, saturated fat, and cholesterol) contribute to the dyslipidemias seen in countries around the world. For many individuals, alterations in lifestyle have a far greater potential for reducing vascular disease risk and at a lower cost than drug therapy. When pharmacotherpy is indicated, providers can choose from multiple agents with proven efficacy...."
The content above is only an excerpt.
For full access, log into an existing user account below,
purchase an annual subscription, or
purchase a short-term subscription to the complete website.
|
|
|
|
Or
|
|
|
|